Ann: Operational Update-PYC.AX, page-12

Preclinical deals were discussed in PYC’s Investor Presentation in April. It was noted that these deals were trending to a higher value and that more than half of top value licensing deals in 2013 and 2014 involved preclinical/discovery assets. Also noted was that more than half of preclinical deals were in cancer and that the median preclinical upfront deal value was US$16m.

Below is information on some preclinical and discovery stage deals that were struck in April and May, which I thought might be of interest. Information is sourced from PM Live, Deal Watch.

http://www.pmlive.com/pharma_intelligence/deal_watch_april_2016_1030920
http://www.pmlive.com/pharma_intelligence/deal_watch_may_2016_1038601

	Column 1	Column 2	Column 3	Column 4	Column 5
0	Licensor ​	Licensee​	Deal type​	Product technology​	Headline $m​
1	ZymeWorks​	GSK​	License and option​	Preclinical bi-specific antibodies based on Azymetric platform for treatment of solid tumours​	908 ​
2	Argenx​	AbbVie​	Option to license and co-promote​	Preclinical ARGX115 antibody programme targetting GARP protein for treatment of cancer​	685 40 upfront
3	CytomX​	AbbVie​	License to promote and co-promote​	Preclinical CD71 Probody Drug Conjugates for three targets for treatment of cancer​	500 30 upfront
4	Intellia​	Regeneron​	Co-development & co-commercialisation​	Discovery stage CRISPR/Cas platform for treatments of liver disease​	125 ​
5	Enumeral​	Pieris​	License & option to further programme​	Discovery state 388D4 programme of PD1 Monoclonal Antibodies immunotherapies​	106​
6	MacroGenics​	J & J​	Licence​	Second bispecific molecule, MGD015, to fight haematologic cancers as well as solid tumours. Said to have strong preclinical data​	740 75 upfront​
7	Carna Biosciences​	ProNAi Therapeutics​	Licence​	AS-141, a small molecule kinase inhibitor targeting CDC7 which demonstrated compelling anti-tumour activity against multiple tumour types in preclinical studies​	271 $0.9m upfront
8	WaVe Life Sciences​	Pfizer​	Licence and collaboration​	Nucleic acid therapies for metabolic disorders. WaVe to advance up to 5 programs from discovery through to the selection of clinical candidates. Pfizer then may elect to exclusively license the programs and undertake further development and potential commercialisation​	911 40 m upfront